Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review

KI Notarte, AT Ver, JV Velasco, A Pastrana… - Critical reviews in …, 2022 - Taylor & Francis
With the advent of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
pandemic, several vaccines have been developed to mitigate its spread and prevent …

Overview of neutralizing antibodies and their potential in COVID-19

JJ Morales-Núñez, JF Muñoz-Valle… - Vaccines, 2021 - mdpi.com
The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a
major focus of COVID-19 research due to its clinical relevance and importance in vaccine …

Real-world COVID-19 vaccine effectiveness against the Omicron BA. 2 variant in a SARS-CoV-2 infection-naive population

JJ Lau, SMS Cheng, K Leung, CK Lee, A Hachim… - Nature medicine, 2023 - nature.com
Abstract The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and
escape of vaccine-derived immunity. Although first-generation vaccines remain effective …

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

A Fendler, STC Shepherd, L Au, KA Wilkinson, M Wu… - Nature cancer, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …

Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection

Y Yang, M Yang, Y Peng, Y Liang, J Wei, L Xing… - Nature …, 2022 - nature.com
Elucidating the dynamics of the neutralizing antibody (nAb) response in coronavirus disease
2019 (COVID-19) convalescents is crucial in controlling the pandemic and informing …

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2· 57 million people in Scotland (EAVE II): a prospective cohort …

U Agrawal, SV Katikireddi, C McCowan… - The Lancet …, 2021 - thelancet.com
Summary Background The UK COVID-19 vaccination programme has prioritised vaccination
of those at the highest risk of COVID-19 mortality and hospitalisation. The programme was …

[HTML][HTML] T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre …

A Angyal, S Longet, SC Moore, RP Payne… - The Lancet …, 2022 - thelancet.com
Background Previous infection with SARS-CoV-2 affects the immune response to the first
dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and …

[HTML][HTML] Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers

G Moncunill, R Aguilar, M Ribes, N Ortega, R Rubio… - …, 2022 - thelancet.com
Background Two doses of mRNA vaccination have shown> 94% efficacy at preventing
COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize …

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

KS Hensley, MJ Jongkees, D Geers… - PLoS …, 2022 - journals.plos.org
Background Vaccines can be less immunogenic in people living with HIV (PLWH), but for
SARS-CoV-2 vaccinations this is unknown. In this study we set out to investigate, for the …

Pfizer-BioNTech and Sinopharm: a comparative study on post-vaccination antibody titers

R Alqassieh, A Suleiman, S Abu-Halaweh, A Santarisi… - Vaccines, 2021 - mdpi.com
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different
mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects …